Literature DB >> 29423542

Evaluation of growth hormone response to GHRH plus arginine test in children with idiopathic short stature: role of peak time.

M Castagno1, A Monzani1, S Zanetta1, G Genoni1, E Giglione1, R Ricotti1, G Bona1, F Prodam2,3,4, S Bellone1,5.   

Abstract

PURPOSE: To describe the course of growth hormone response to growth hormone releasing hormone (GHRH) plus arginine provocative test in children with idiopathic short stature (ISS) and to evaluate the role of peak time.
METHODS: A retrospective study was performed analyzing 344 GHRH plus arginine provocative tests performed in children and adolescents with short stature. Serum GH levels were measured at four-time points (T0', T30', T45' and T60') and GH peak was defined as the maximum value at any time point. Mean (T30'-T60') GH value and area under the curve (AUC) were calculated.
RESULTS: When analyzing the time of peak at the provocative test, the most frequent peak time was T45' (53.8%) in the ISS group, with no differences in gender, age, and pubertal stage. Analyzing GHD subjects, the most frequent time of peak was T30 (50%). Analyzing the whole population, the GH T0' levels were significantly lower in subjects with the GH peak at T45' than those with the GH peak at T30' (1.7 ± 2.0 vs. 3.2 ± 4.0, p < 0.001). In subjects with GH peak at T45', the value of GH peak, AUC and mean GH were significantly higher than in those with GH peak at T30' and T60'. A direct correlation was found between the value of GH peak and growth velocity SDS (r = 0.127, p = 0.04) and a negative one between GH peak and GH level at T0' (r = - 0.111, p = 0.04), even when adjusted for gender, age, pubertal stage and BMI Z score.
CONCLUSIONS: The time peak at 45 min seems to be associated with a better response to the test considering GH peak, mean and AUC. Patients with a GH peak at 30 min more probably could have a derangement in GH secretion showing worst growth pattern and/or a GH deficiency and should be carefully observed.

Entities:  

Keywords:  GHRH plus arginine test; Growth hormone; Idiopathic short stature; Peak time

Mesh:

Substances:

Year:  2018        PMID: 29423542     DOI: 10.1007/s40618-017-0824-6

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  26 in total

1.  Influence of body mass index and gender on growth hormone (GH) responses to GH-releasing hormone plus arginine and insulin tolerance tests.

Authors:  Xiao-Dan Qu; Irene T Gaw Gonzalo; Mohammed Y Al Sayed; Pejman Cohan; Peter D Christenson; Ronald S Swerdloff; Daniel F Kelly; Christina Wang
Journal:  J Clin Endocrinol Metab       Date:  2004-12-21       Impact factor: 5.958

Review 2.  The diagnosis of growth hormone deficiency in children and adults.

Authors:  S M Shalet; A Toogood; A Rahim; B M Brennan
Journal:  Endocr Rev       Date:  1998-04       Impact factor: 19.871

3.  Sequential administration of arginine and arginine plus GHRH to test somatotroph function in short children.

Authors:  J Bellone; G Aimaretti; S Bellone; C Baffoni; G Corneli; C Origlia; M Cappa; E Ghigo
Journal:  J Endocrinol Invest       Date:  2000-02       Impact factor: 4.256

4.  Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man.

Authors:  E Ghigo; S Goffi; M Nicolosi; E Arvat; F Valente; E Mazza; M C Ghigo; F Camanni
Journal:  J Clin Endocrinol Metab       Date:  1990-12       Impact factor: 5.958

5.  Reliability of provocative tests to assess growth hormone secretory status. Study in 472 normally growing children.

Authors:  E Ghigo; J Bellone; G Aimaretti; S Bellone; S Loche; M Cappa; E Bartolotta; F Dammacco; F Camanni
Journal:  J Clin Endocrinol Metab       Date:  1996-09       Impact factor: 5.958

6.  Validation of the Italian Quality of Life in Short Stature Youth (QoLISSY) questionnaire.

Authors:  J Quitmann; A Giammarco; M Maghnie; F Napoli; I Di Giovanni; C Carducci; A Mohn; M Bullinger; R Sommer
Journal:  J Endocrinol Invest       Date:  2017-04-10       Impact factor: 4.256

7.  Basal plasma growth hormone levels in man: new evidence for rhythmicity of growth hormone secretion.

Authors:  L M Winer; M A Shaw; G Baumann
Journal:  J Clin Endocrinol Metab       Date:  1990-06       Impact factor: 5.958

8.  Short procedure of GHRH plus arginine test in clinical practice.

Authors:  G Aimaretti; S Bellone; C Baffoni; G Cornel; C Origlia; L Di Vito; S Rovere; E Arvat; F Camanni; E Ghigo
Journal:  Pituitary       Date:  2001-08       Impact factor: 4.107

9.  The arginine stimulation test: timing of peak is not a helpful parameter in the diagnosis of growth hormone deficiency.

Authors:  David Gillis; Nadav Granat; David Strich
Journal:  J Pediatr Endocrinol Metab       Date:  2013       Impact factor: 1.634

10.  Efficacy and safety of growth hormone treatment in children with short stature: the Italian cohort of the GeNeSIS clinical study.

Authors:  M Cappa; L Iughetti; S Loche; M Maghnie; A Vottero
Journal:  J Endocrinol Invest       Date:  2015-12-28       Impact factor: 4.256

View more
  2 in total

Review 1.  The use of prohibited substances for therapeutic reasons in athletes affected by endocrine diseases and disorders: the therapeutic use exemption (TUE) in clinical endocrinology.

Authors:  L Di Luigi; F Pigozzi; P Sgrò; L Frati; A Di Gianfrancesco; M Cappa
Journal:  J Endocrinol Invest       Date:  2019-11-16       Impact factor: 4.256

2.  Diagnosis of Idiopathic GHD in Children Based on Response to rhGH Treatment: The Importance of GH Provocative Tests and IGF-1.

Authors:  João Soares Felício; Luísa Corrêa Janaú; Marcelle Alves Moraes; Nathalie Abdallah Zahalan; Fabrício de Souza Resende; Manuela Nascimento de Lemos; Norberto Jorge Kzan de Souza Neto; Isabela Imbelloni Farias de Franco; Loyane Tamyres Costa Leitão; Lilian de Souza d'Albuquerque Silva; Maria Clara Neres Iunes de Oliveira; Angélica Leite de Alcântara; Ana Carolina Contente Braga de Souza; Wanderson Maia da Silva; Márcia Costa Dos Santos; Natércia Neves Marques de Queiroz; Lorena Vilhena de Moraes; Antônio Bentes de Figueiredo; Ana Luiza Prieto Farinassi; Luciana Marques da Costa Farias; Danielle Dias da Silva; Karem Miléo Felício; João Felício Abrahão Neto
Journal:  Front Endocrinol (Lausanne)       Date:  2019-09-19       Impact factor: 5.555

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.